

2024 Step Therapy Criteria

Updated 10/15/2023

URINARY ANTISPASMODICS

Products Affected

Step 1:

- fesoterodine ER 4 mg tablet,extended release 24 hr
- fesoterodine ER 8 mg tablet,extended release 24 hr
- Gemtesa 75 mg tablet
- Myrbetriq 25 mg tablet,extended release
- Myrbetriq 50 mg tablet,extended release
- Myrbetriq 8 mg/mL oral suspension,extended release
- oxybutynin chloride 5 mg tablet
- oxybutynin chloride 5 mg/5 mL oral syrup
- oxybutynin chloride ER 10 mg tablet,extended release 24 hr
- oxybutynin chloride ER 15 mg tablet,extended release 24 hr
- oxybutynin chloride ER 5 mg tablet,extended release 24 hr
- solifenacin 10 mg tablet
- solifenacin 5 mg tablet
- tolterodine 1 mg tablet
- tolterodine 2 mg tablet
- trospium 20 mg tablet

Step 2:

- tolterodine ER 2 mg capsule,extended release 24 hr
- tolterodine ER 4 mg capsule,extended release 24 hr

Details

Criteria	Coverage will be provided if fesoterodine, mirabegron, oxybutynin, oxybutynin extended-release, solifenacin tablets, tolterodine tablets, trospium immediate-release, or vibegron has been tried (at least a 30-day supply in the prior 180 days).
-----------------	--

